ALFA Finder
14:38 IST
BSE
Earnings Call
Alembic Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹26.03bn (+36% YoY), PAT ₹3.35bn (+81%), EBITDA margin 22% (+520bps). US formulations led growth (+77%).
Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd news stories on ALFA NewsRead the news →- Share price
- ₹1,029.95
- Market cap
- ₹20,245 Cr
- Revenue (annual)
- ₹7,345 Cr
- Net profit (annual)
- ₹674.8 Cr
- P/E (TTM)
- 24.0×Sector 43.8×
- Promoter holding
- 69.87%+0.00% QoQ
- FII holding
- 4.55%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Debt & Borrowing 9Regulatory Approval 8Earnings Call 6Merger & Restructuring 5Management Change 5Business Update 5Financial Results 4Results Update 3Other Announcement 3Credit Rating 2Board Meeting Date 2Annual General Meeting 2Partnership 1Legal & Regulatory 1Dividend 1Capital Structure Change 1Annual Report 1
Time
6 announcements with these filters
12:54 IST
BSE
Earnings Call
Alembic Pharmaceuticals Investor Presentation: Key Takeaways
Q1FY27 revenue grew 26% to INR 2,150 Cr. Strategy focuses on US Generics volume growth, India Specialty therapeutic scale-up, and managing margin dilution from US branded investments.
- Call
- Guides 15% growth
14:14 IST
NSE
Earnings Call
Alembic Pharmaceuticals Investor Presentation: Key Takeaways
Alembic Pharma delivered strong Q1 FY27 results with 26% revenue growth, driven by a 49% surge in US formulations. Strategy focuses on specialty US branded expansion and peptide development.
15:30 IST
BSE
Earnings Call
Alembic Pharmaceuticals Earnings Call: Key Takeaways
Alembic Pharma delivered Q4 FY26 revenue of ₹1,838 Cr (up 4% YoY) and PAT of ₹203 Cr. FY26 revenue grew 10% YoY to ₹6,201 Cr with 25% EBITDA margins before R&D.
18:37 IST
NSE
Earnings Call
Alembic Pharmaceuticals Earnings Call: Key Takeaways
Management showcases a 100-year legacy transitioning into a high-tech global pharmaceutical player through massive facility expansion and R&D focus.
14:51 IST
NSE
Earnings Call
Alembic Pharmaceuticals Earnings Call: Key Takeaways
Alembic Pharma reported Q4FY26 revenue of INR 18.48 Bn, up 4% YoY, and PAT of INR 2.03 Bn, up 29% YoY. The company launched its first branded product, Pivya, in the US.